Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Knight Therapeutics Inc.TSX: GUD.TO

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of CA$3.33M (cash outflow) fell 10.1% year over year, behind the +21.1% change in trailing-twelve-month capital expenditures. Sequentially, it rose 558.6% from the prior quarter. Over 3 fiscal years it compounded at -58.0% a year.

Context

  • Capital expenditures amounted to 0.4% of revenue in FY2025, down 8.1 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.1% toward the trailing-twelve-month pace of +21.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$3.33M+558.6% QoQ
Last fiscal yearDec 2025
-CA$1.91M-93.9% YoY
LTMMar 2026
-CA$29.37M+21.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.1%——
1 year-93.9%——
3-year CAGR-58.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CAD · from the cash flow

Latest · FY2025
(1.91M) CAD
Year-over-year change
+93.9%

Capital Expenditures vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +21.1% is the 2nd highest of 8, against a peer median of -37.4%.
  • Capital expenditures amounts to 5.8% of revenue for GUD.TO, versus a peer median of 2.6%.
GUD.TO Competitors
Capital Expenditures for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$29.37M CAD+21.1%-58.0%5.8%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$22.55M CAD+19.5%+22.9%7.1%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$11.19M CAD+1.5%—4.1%
TSND.TOTerrAscend Corp.LTM Mar 2026$6.87M USD-37.4%-45.7%2.6%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$6.44M CAD-42.9%-17.4%2.1%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$5.69M CAD-72.4%-72.1%8.6%
VHI.TOVitalhub Corp.LTM Mar 2026CA$409.83K CAD-54.1%+12.8%0.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$107.42K USD+168.5%-29.4%0.2%
Peer median (excluding GUD.TO) —-37.4%-23.4%2.6%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
Deferred Income Tax(7.64M)(17.13M)(9.13M)(3.24M)(3.81M)
Stock-Based Compensation3.05M1.89M2.33M1.86M8.11M
Change in Working Capital627K(9.99M)(28.01M)(19.62M)1.89M
Accounts Receivables8.59M(26.42M)5.58M(10.29M)(26.53M)
Inventory(17.19M)(11.43M)698K(5.91M)(17.82M)
Accounts Payables11.46M30.6M(21.63M)632K42.11M
Other Working Capital(2.23M)(2.74M)(12.66M)(4.06M)4.14M
Other Non-Cash Items(15.01M)32.98M37.19M(154K)12.91M
Operating Cash Flow44.62M40.48M35.94M36.28M70.3M
Capital Expenditures(224.18M)(25.82M)(9.96M)(31.47M)(1.91M)
Acquisitions (Net)(220.35M)000(110.05M)
Purchases of Investments(64.32M)(185.47M)(334.16M)(162.57M)(70.39M)
Sales of Investments180.54M150.54M345.47M196.12M112.43M
Other Investing Activities223.04M(2.33M)18.99M(14.12M)17.6M
Investing Cash Flow(105.28M)(63.08M)29.34M16.96M(84.11M)
Debt Repayment(14.19M)31.49M(18.02M)(18.05M)23.19M
Common Stock Issued0000511K
Common Stock Repurchased(64.42M)(30.07M)(53.48M)(8.87M)(6.35M)
Dividends Paid00000
Other Financing Activities297K(4.18M)(9.5M)(6.62M)(4.34M)
Financing Cash Flow(78.31M)1.76M(81M)(33.54M)13.01M
Effect of Forex Changes(4.66M)6.55M2.8M1.64M(2.86M)
Net Change in Cash(143.63M)(14.28M)(12.92M)21.35M(3.66M)
Free Cash Flow(179.57M)14.67M25.98M4.81M68.4M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.